Q-omics provides the consensus-scored TBC1D26 profile across patient tissues and cancer cell-line models. TBC1D26 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TBC1D26 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, TBC1D26 RNA expression shows 11,960 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where TBC1D26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D26 survival associations across molecular data types. TBC1D26 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D26 RNA expression–survival associations across cancer types. High TBC1D26 expression shows unfavorable associations in KIRC, CHOL and READ, but favorable associations in HNSC, UCS and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TBC1D26 RNA expression.
This table summarizes TBC1D26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TBC1D26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D26 shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, KIRC and UCEC. The LUAD box plot shows higher TBC1D26 RNA expression in normal versus tumor tissue (log2 FC = −0.234, t-test p < 0.001).
This table shows molecular features associated with TBC1D26 in patient tissues and cancer cell lines. In patient samples, TBC1D26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SKIN.
